youtube_live
Q3 2026 earnings • released • EPS beat +74.28% • Revenue beat +7.49%
See resultschevron_right
ONC:NASDAQ
BeOne Medicines AG
$415.80
arrow_upward
+2.17%(+8.84) 1D
Nov 9, 10:18:51 AM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ONC...
Open
$410.00
High
$415.80
Low
$409.80
Mkt. cap
49.26B
Avg. vol.
419.68K
Volume
112.86K
52-wk high
$415.80
52-wk low
$409.80
Beta
0.63
Shares outstanding
109.79M
No. of employees
12K
Open
$410.00
High
$415.80
Low
$409.80
Mkt. cap
49.26B
Avg. vol.
419.68K
Volume
112.86K
52-wk high
$415.80
52-wk low
$409.80
Beta
0.63
Shares outstanding
109.79M
No. of employees
12K
News stories
From web sources and news partners
Investing.com Nigeria
·
2 days ago
Form 144 BeOne Medicines Ltd. For: 6 November By Investing.com
Profile
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
About BeOne Medicines AG
CEOJohn Vincent Oyler | John Vincent Oyler
Employees12K
FoundedOct 28, 2010
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitebeonemedicines.com